CLN-081

DRUG2 trials

Sponsors

Cullinan Pearl Corp., Cullinan Therapeutics Inc.

Conditions

EGFR Exon 20 MutationNon Small Cell Lung CancerNon-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Phase 1

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Active, not recruitingNCT04036682

Cullinan Therapeutics Inc.EGFR Exon 20 Mutation, Non Small Cell Lung Cancer

Start: 2019-10-31End: 2028-03-31Target: 284Updated: 2026-06-17

A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Active, not recruitingCTIS2024-516532-97-00

Cullinan Pearl Corp.Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Start: 2020-03-26Target: 63Updated: 2025-03-10

Related Papers

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab

Journal of Clinical Oncology2025-06-015 citations

Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

Journal of Clinical Oncology2025-05-28

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science2024-03-0116 citations

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

Journal of Clinical Oncology2022-06-0132 citations

Advanced lung adenocarcinoma patient with <i>EGFR</i> exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report.

2022-03-0110 citations

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

Journal of Clinical Oncology2021-05-2033 citations